Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
CAT | Size | Price | Quantity | |
---|---|---|---|---|
LBST-057FG |
|
Product Information | |
---|---|
Product Overview | Bifidobacterium longum is a Gram-positive, catalase-negative, rod-shaped bacterium present in the human gastrointestinal tract. |
Target | Bifidobacterium |
Genus | Bifidobacterium |
Application | Study and research |
Type Strain | Yes |
Culture Medium | CM0233 |
Culture Conditions | 37°C; Anaerobic |
Characteristics | The formation of biofilm is conducive to adhesion and colonization. |
Risk Group | 1 |
Product Format | Freeze-dried |
Packaging | Ampoule tube |
Storage | -80°C |
Shelf Life | 6 years |
Target Introduction | |
---|---|
Introduction | Bifidobacterium are Gram-positive, heterofermentative, anaerobic bacteria with a distinctive bifid; i.e. Y shape after which they are named. They wre originally isolated from the faeces of breast-fed infants, members of the genus Bifidobacterium are commonly found in the GI tract of mammals. In humans, Bifidobacterium resides within the GI tract, from birth to old age. Disturbances in the microbiota are linked to an ever-growing number of immune-linked disease states including IBD, atopic allergy, arthritis, and obesity. Therefore, there is a significant interest in treating these diseases through microbial or "probiotic" supplementation of patients, including Bifidobacterium. Data from mouse models and clinical trials indicate that Bifidobacterium may have beneficial effects for treating and preventing immune-linked diseases, including gut-associated and systemic conditions. Bifidobacterium have been commercially exploited as probiotic agents due to their associated health benefits and GRAS; Generally Recognised As Safe status. |
Alternative Names | Bifidobacterium longum subsp. infantis |
Bifidobacterium longum subsp. infantis is typically prepared by fermentation, followed by freezing and freeze-drying to maintain viability. The bacteria are often mixed with cryoprotectants during preparation. For use, the freeze-dried powder is reconstituted in an appropriate medium or directly added to the experimental setup. Proper preparation is essential to ensure the stability and efficacy of the bacteria throughout the research process.
When using Bifidobacterium longum subsp. infantis in experiments, it is critical to include appropriate controls such as placebo groups or non-treated samples. This helps in accurately determining the effects of the bacteria. Additionally, ensuring that the bacterial preparation is free from contaminants and adheres to strain-specific standards is crucial for the validity of the study.
For culturing Bifidobacterium longum subsp. infantis, a suitable anaerobic environment must be maintained. The bacteria should be cultured in a medium rich in nutrients that support its growth, such as MRS broth. Incubation typically occurs at 37°C for 24-48 hours. Maintaining anaerobic conditions is critical to ensure the proper growth and activity of the bacteria.
The stability of Bifidobacterium longum subsp. infantis during long-term storage can be ensured by keeping it at -80°C in a lyophilized form. Adding cryoprotectants during the preparation process can protect the bacteria from damage during freezing and thawing. Regular viability checks are recommended to ensure the bacteria remain effective for research purposes.
Common quality control measures for Bifidobacterium longum subsp. infantis include DNA sequencing, PCR-based methods, and phenotypic analysis to verify the identity of the strain. Purity can be assessed by culturing the bacteria on selective media and conducting contaminant testing. Ensuring the strain's genetic stability and purity is crucial for obtaining accurate and reliable research results.
Growth on HMOs of select B. infantis strains
The study highlights the genetic variability in the utilization of human milk oligosaccharides (HMOs) among B. infantis strains. The study analyzed twelve probiotic strains and identified two key variants in the HMO utilization gene clusters. Specifically, some strains, termed H5-positive, possessed a full set of HMO utilization genes, including an ABC-type transporter, while H5-negative strains lacked this transporter. This genetic distinction resulted in significant differences in the strains' growth capabilities on specific HMOs, such as lacto-N-tetraose and lacto-N-neotetraose.
The experimental data underscored that H5-positive strains exhibited superior growth in both in vitro and in vivo conditions. For instance, the study demonstrated that in breastfed infants, H5-positive strains showed a significant fitness advantage over H5-negative strains. This research underscores the importance of genetic profiling in selecting probiotic strains for infant gut health, highlighting that the presence of specific HMO utilization genes can greatly enhance the efficacy of B. infantis strains in promoting a healthy infant microbiome.
Duar, Rebbeca M., et al. "Comparative genome analysis of Bifidobacterium longum subsp. infantis strains reveals variation in human milk oligosaccharide utilization genes among commercial probiotics." Nutrients 12.11 (2020): 3247.
Click the button below to contact us or submit your feedback about this product.
For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.
Copyright © 2024 Creative Biolabs. All Rights Reserved.